Cargando…

Evaluating different breast tumor progression models using screening data

BACKGROUND: Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels a...

Descripción completa

Detalles Bibliográficos
Autores principales: Westvik, Åsbjørn Schumacher, Weedon-Fekjær, Harald, Mæhlen, Jan, Liestøl, Knut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819671/
https://www.ncbi.nlm.nih.gov/pubmed/29463227
http://dx.doi.org/10.1186/s12885-018-4130-2
_version_ 1783301248244514816
author Westvik, Åsbjørn Schumacher
Weedon-Fekjær, Harald
Mæhlen, Jan
Liestøl, Knut
author_facet Westvik, Åsbjørn Schumacher
Weedon-Fekjær, Harald
Mæhlen, Jan
Liestøl, Knut
author_sort Westvik, Åsbjørn Schumacher
collection PubMed
description BACKGROUND: Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels after introducing mammography screening can be reproduced assuming only progressive tumors. METHODS: Breast cancer incidence data 1990–2009 obtained from the initially screened Norwegian counties (Akershus, Oslo, Rogaland and Hordaland) was included, covering the time-period before, during and after the introduction of mammography screening. From 1996 women aged 50–69 were invited for biennial public screening. Using estimates of tumor growth and screening sensitivity based on pre-screening and prevalence screening data (1990–1998), we simulated incidence levels during the following period (1999–2009). RESULTS: The simulated incidence levels during the period with repeated screenings were markedly below the observed levels. The results were robust to changes in model parameters. Adjusting for hormone replacement therapy use, we obtained levels closer to the observed levels. However, there was still a marked gap, and only by assuming some tumors that undergo regressive changes or enter a markedly less detectable state, was our model able to reproduce the observed incidence levels. CONCLUSIONS: Models with strictly progressive tumors are only able to partly explain the changes in incidence levels observed after screening introduction in the initially screened Norwegian counties. More complex explanations than a time shift in detection of future clinical cancers seem to be needed to reproduce the incidence trends, questioning the basis for many over-diagnosis calculations. As data are not randomized, similar studies in other populations are wanted to exclude effect of unknown confounders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4130-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5819671
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58196712018-02-26 Evaluating different breast tumor progression models using screening data Westvik, Åsbjørn Schumacher Weedon-Fekjær, Harald Mæhlen, Jan Liestøl, Knut BMC Cancer Research Article BACKGROUND: Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels after introducing mammography screening can be reproduced assuming only progressive tumors. METHODS: Breast cancer incidence data 1990–2009 obtained from the initially screened Norwegian counties (Akershus, Oslo, Rogaland and Hordaland) was included, covering the time-period before, during and after the introduction of mammography screening. From 1996 women aged 50–69 were invited for biennial public screening. Using estimates of tumor growth and screening sensitivity based on pre-screening and prevalence screening data (1990–1998), we simulated incidence levels during the following period (1999–2009). RESULTS: The simulated incidence levels during the period with repeated screenings were markedly below the observed levels. The results were robust to changes in model parameters. Adjusting for hormone replacement therapy use, we obtained levels closer to the observed levels. However, there was still a marked gap, and only by assuming some tumors that undergo regressive changes or enter a markedly less detectable state, was our model able to reproduce the observed incidence levels. CONCLUSIONS: Models with strictly progressive tumors are only able to partly explain the changes in incidence levels observed after screening introduction in the initially screened Norwegian counties. More complex explanations than a time shift in detection of future clinical cancers seem to be needed to reproduce the incidence trends, questioning the basis for many over-diagnosis calculations. As data are not randomized, similar studies in other populations are wanted to exclude effect of unknown confounders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4130-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-20 /pmc/articles/PMC5819671/ /pubmed/29463227 http://dx.doi.org/10.1186/s12885-018-4130-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Westvik, Åsbjørn Schumacher
Weedon-Fekjær, Harald
Mæhlen, Jan
Liestøl, Knut
Evaluating different breast tumor progression models using screening data
title Evaluating different breast tumor progression models using screening data
title_full Evaluating different breast tumor progression models using screening data
title_fullStr Evaluating different breast tumor progression models using screening data
title_full_unstemmed Evaluating different breast tumor progression models using screening data
title_short Evaluating different breast tumor progression models using screening data
title_sort evaluating different breast tumor progression models using screening data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819671/
https://www.ncbi.nlm.nih.gov/pubmed/29463227
http://dx.doi.org/10.1186/s12885-018-4130-2
work_keys_str_mv AT westvikasbjørnschumacher evaluatingdifferentbreasttumorprogressionmodelsusingscreeningdata
AT weedonfekjærharald evaluatingdifferentbreasttumorprogressionmodelsusingscreeningdata
AT mæhlenjan evaluatingdifferentbreasttumorprogressionmodelsusingscreeningdata
AT liestølknut evaluatingdifferentbreasttumorprogressionmodelsusingscreeningdata